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Key points: Combination flucytosine (5FC) plus fluconazole (FLU) is highly cost 
effective, compared with the commonly used regimen of FLU monotherapy, for 
cryptococcal meningitis treatment in Africa; with an incremental cost-effectiveness 
ratio of US$65 per life year saved at current 5FC price.  
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Abstract  
Background  
Mortality from cryptococcal meningitis remains very high in Africa.  In the ACTA trial, 
2 weeks of fluconazole (FLU) plus flucytosine (5FC) was as effective and less costly 
than 2-week amphotericin B-based regimens. However, many African settings treat 
with FLU monotherapy and the cost effectiveness of adding 5FC to FLU is uncertain.  
Methods  
The  effectiveness and costs of FLU+5FC were taken from ACTA, which included a 
costing analysis at the Zambian site. The effectiveness of FLU was derived from 
cohorts of consecutively enrolled patients, managed in respects other than drug 
therapy, as were participants in ACTA. FLU costs were derived from the costs of 
FLU+5FC in ACTA, by subtraction of 5FC drug costs and 5FC monitoring tests. 
Cost-effectiveness of FLU+5FC vs FLU alone was measured as the incremental 
cost-effectiveness ratio (ICER). Probabilistic sensitivity analysis assessed 
uncertainties, and a bivariate deterministic sensitivity analysis examined the impact 
of varying mortality estimates and 5FC drug costs on the ICER. 
Results  
Mean costs per patient were US$847 (95%CI:776-927) for FLU+5FC, and US$628 
(95%CI:557-709) for FLU. 10 week mortality was 35.1% (95%CI 28.9-41.7) with 
FLU+5FC and 53.8% (95%CI: 43.1–64.1) with FLU. At the current 5FC price of 
$US1.30 per 500mg tablet, the ICER of 5FC+FLU versus FLU alone was US$65 
(95%CI: 28-208) per life year saved. Reducing 5FC cost to between US$0.80 and 
US$0.40 per 500mg resulted in an ICER between US$44 and US$28 per life year 
saved. 
Conclusions  
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Addition of 5FC to FLU is cost effective for cryptococcal meningitis treatment in 
Africa and if made available widely could substantially reduce mortality rates among 
HIV-infected persons in Africa.  
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Background 
Mortality from cryptococcal meningitis (CM) remains unacceptably high in Sub-
Saharan Africa [1]. The most widely used treatment, fluconazole (FLU) monotherapy 
is associated with mortality of 50-60% at 10 weeks and >70% at 1 year, even in 
study cohorts [2-5]. Access to amphotericin B and, in particular, flucytosine is 
currently limited, despite the fact that the latter is off patent and a relative simple 
molecule to manufacture. 
 
The ACTA trial [6] recently tested new induction treatment strategies. Two weeks 
oral combination therapy with FLU+flucytosine (5FC), and short, 1-week, 
amphotericin B (AmB) regimens, were compared against the internationally 
recommended 2 week AmB-based induction regimen. The aim was to improve upon 
the efficacy of FLU monotherapy with regimens that could be sustained in resource-
limited settings.  
 
While 1 week AmB+5FC was the regimen associated with the lowest mortality in the 
trial, the oral combination of FLU+5FC was non-inferior compared with the then 
recommended regimen of 2 weeks of AmB+5FC. Furthermore, in a detailed cost 
effectiveness analysis, oral FLU+5FC was the least expensive regimen [7]. Thus, for 
resource limited centres currently using FLU monotherapy, where even one week of 
AmB would be difficult to sustain, oral FLU+5FC is an attractive option, and new 
WHO guidelines following the trial recommend this option if AmB is not available [8]. 
 
The ACTA trial did not include an arm treated with fluconazole monotherapy, due to 
lack of equipoise. In addition, changing clinical practice in centres currently treating 
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with FLU will be a challenge because of resource constraints. Therefore, to inform 
local policy and practice, and guide efforts to improve flucytosine access, we have 
conducted an analysis of the cost-effectiveness of oral FLU+5FC versus FLU 
monotherapy.  
 
Methods 
The costs and effectiveness of FLU+5FC were derived from the ACTA trial [6]. ACTA 
was a large open label, phase 3, randomised non-inferiority, multi-centre trial, in 
which 721 patients with HIV-associated cryptococcal meningitis from centres in 
Malawi, Zambia, Tanzania and Cameroon were randomised to three strategies: 2 
weeks oral FLU+5FC, 1 week AmB, and standard 2 weeks AmB, and those in the 
AmB arms were further randomised to 5FC or FLU in a 1:1 ratio, as the partner drug 
given with AmB.  
 
A full economic costing and cost-effectiveness analysis of the ACTA treatments was 
done from the health care perspective [7]. Resource use data were collected using 
an ingredients-based approach [9]. The data on individual resource use and health 
outcomes, including trial-related complications and treatment of complications, were 
collected from all participants onto case-report forms (CRFs). A detailed costing 
study was done in the Zambian hospital, including CM-specific and overhead costs, 
including costs of admissions and laboratory tests. Prices were adjusted to 2015 
US$ price level for consistency with our prior analysis [7]. Of note however, the 
inflation change for 2015 to 2018 was modest at 5.9%. 
 
The costs of FLU+5FC in this study were derived from the ACTA analysis of 
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FLU+5FC cost, adapted to a short stay scenario, reflective of the duration of 
hospitalisation in implementation, as opposed to that within the trial (Supplementary 
Table S1). In the trial, participants were asked for safety monitoring reasons to stay 
for 14 days in hospital. Thus, in this scenario, we presumed one week of 
hospitalisation for patients treated with FLU+5FC and for those treated with FLU 
alone, plus an average of 2 days of re-hospitalisation, as observed in the ACTA trial. 
Hospitalisation costs were US$47.65 per day, giving a total cost of US$428.85 per 
patient. Of note, all CM patients, including those treated with oral drugs, require 
some days of hospitalisation for optimal care, including measurement and 
management of raised cerebrospinal fluid pressure.  
 
CM-treatment-specific costs, diagnostics, drug costs, laboratory monitoring, 
complication-related resource use, hospital care, equipment and personnel costs 
were considered (Supplementary Table S1). The cost of FLU was US$0.55 per 
200mg tablet, with a 14 day course costing US$7.70. The 5FC cost was $US1.30 
per 500 mg tablet, taken from the current cost of procurement for the AMBITION trial 
(ISRCTN10248064). Thus for a 50 kg patient, the cost for 2 weeks was US$182. 
 
Laboratory costs included biochemistry tests as used in the ACTA trial for individual 
patient care, as well as routine baseline and one follow-up test for electrolytes, urea 
and creatinine, and ALT. A routine follow-up full blood count was costed for the oral 
combination to monitor for neutropenia with 5FC. Blood, cerebrospinal fluid (CSF) 
and sputum cultures as used for patient care, and the cost of antibiotics used to treat 
other infections was included. A single CD4 count and an average of 3 lumbar 
punctures during hospitalisation for each patient were included.  
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The total costs of FLU monotherapy are derived from the costs of FLU+5FC, from 
the  ACTA trial data, as above, by subtraction of the day 7 5FC monitoring full blood 
count and 5FC drug costs (Supplementary Table S1).  
 
Mortality at 10 weeks in the 5FC+FLU combination arm of the ACTA trial was 79/225 
(35.1%,95% CI: 28.9 – 41.7). For the effectiveness of FLU treatment, we analysed 
data from research participants in 3 cohorts of patients treated with FLU at 1200 
mg/day in Malawi  [2, 5], and Uganda [3]. These research cohorts consisted of 
consecutively enrolled patients with near complete follow-up to 10 weeks. The 2 
Malawi sites were later involved in ACTA, and patient management in all 3 cohorts 
involved members of our group and was similar in all respects other than antifungal 
therapy to the management of participants in the ACTA trial. In the Malawi cohorts, 
10-week mortality was 26/47 [2] and 11/19 [5] while in Uganda it was 13/27 [3], 
giving a weighted mortality of 53.8% (95% CI: 43.1–64.1). The health outcomes 
included in the cost-effectiveness analysis were deaths averted and life years saved. 
The average life expectancy of the additional survivors was estimated conservatively 
at 18 years [10-12].   
 
We conducted a decision analysis to estimate the incremental cost-effectiveness 
ratio of adding 5FC to FLU versus FLU monotherapy. We did a probabilistic 
sensitivity analysis, varying hospital care costs, driven in large part by length of stay, 
and the mortality estimates in the two arms. In the ACTA cost-effectiveness analysis, 
mortality rate was the major driver of the incremental cost-effectiveness ratios [7]. 
Given this, and the current international drive to make 5FC widely available for the 
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treatment of cryptococcal meningitis [13], a bivariate deterministic sensitivity 
analyses was performed by varying mortality rate in the FLU monotherapy arm and 
the cost of 5FC from the currently available price, to explore the changes in the 
incremental cost-effectiveness ratio. A previous cost-effectiveness analysis [10] used 
a theoretical price for a generic 5FC tablet of US$0.44 [14].  
Ethics  
The ACTA trial protocol and data collection was approved by London School of 
Hygiene and Tropical Medicine Research Ethics Committee and by the national 
ethics and regulatory bodies in each country [6]. Written informed consent was 
obtained from all participants or, in the case of those with altered mental status, from 
the next of kin (the participants were re-consented on recovery).  
 
Results 
 
Costs and health outcomes 
The mean total costs per patient were US$847 (95% CI: 776-927) for FLU+5FC 
treatment, and US$628 (95% CI: 557-709) for FLU monotherapy, thus giving 
US$219 (95% CI: 110-329) extra cost for the addition of 5FC to FLU.  
 
The only differences in costs between the two treatments were due to 5FC drug 
costs and full blood count costs (Supplementary Table S2). The total cost (per 
patient) for flucytosine was US$182, making up 21% of the total cost in the oral 
combination arm. Per patient drug costs for FLU alone was US$8, making up 1% of 
the total costs in the FLU monotherapy arm. Hospital costs contributed at least 50% 
of the total cost in both arms.  
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The 10 week mortality with FLU+5FC was 35.1% (95%CI 28.9-41.7) and 53.8% (95% 
CI: 43.1–64.1) with FLU alone. Thus, the risk ratio of FLU+5FC (79/225) versus FLU 
alone (50/93) was 0.65 (95% CI: 0.50 - 0.85).  
 
Cost effectiveness, uncertainty, and sensitivity analyses 
 
The addition of 5FC to FLU was more costly but more effective than FLU 
monotherapy (Table 1). At the current 5FC price of $US1.30 per 500mg tablet, the 
incremental cost-effectiveness ratio of FLU+5FC versus FLU alone was estimated to 
be US$65 (95% CI:28-208) per life year saved. 
 
Figure 1 shows the effect of varying the mortality rate in the FLU arm and the price of 
5FC, on the incremental cost-effectiveness ratio. Increasing the fluconazole mortality 
to 60%, given the ongoing high mortality after 10 weeks seen in fluconazole-treated 
cohorts [4], reduces the ICER to US$49 per life year saved. Reducing the price of 
5FC to US$0.60 per 500 mg tablet, the ICER is reduced by nearly half to US$36 per 
life year saved. If the cost of 5FC was varied from US$0.80 to US$0.40 per 500mg 
tablet, then the incremental cost-effectiveness ratio would be between US$44 and 
US$28, assuming other parameters were constant.  
 
Discussion 
Our analysis demonstrates that adding 5FC to FLU for the treatment of cryptococcal 
meningitis in Africa is cost effective compared with the current practice of fluconazole 
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monotherapy. The estimated ICER for FLU+5FC versus FLU alone was only US$65 
per life year saved, even at the current 5FC price. Reducing the current price of 5FC 
by half, as is expected will be possible [10, 15], makes FLU+5FC even more 
attractive, with the ICER falling below US$40 per life year saved. Thus, the oral 
combination of FLU+5FC will be affordable in many Sub-Saharan African countries. 
The costs compare favourably with those of other interventions that cost around 
US$100 per disability adjusted life year, including treating tuberculosis with first-line 
drugs and treating malaria with artemisinin-based combination therapy [16].  
 
We have used prospectively collected data on patient level resource use from a 
large study to estimate CM treatment-specific costs. Outcome data is from the same 
large trial and from three studies of high dose FLU monotherapy with consecutive 
enrolment, near complete follow-up, and management practice in line with the ACTA 
trial. The mortality rates observed with high dose FLU monotherapy were very similar 
to a prior pooled estimate with use of 800–1200mg FLU (54.9% (95% CI: 46.0 – 
63.5))[17]. Further, our results are comparable to those of a previous study by 
Rajasingham et al that estimated the ICER of FLU+5FC versus FLU alone at US$53 
per quality adjusted life year (QALY), based on a theoretical price of 5FC of US$0.44 
per 500mg tablet [10]. Nevertheless, it is a limitation of the analysis that the mortality 
rates for fluconazole were derived from separate cohorts, rather than from within the 
trial. In addition, unit costs were derived from the Zambian study site, meaning that 
generalization of total costs to other settings must be made with caution. 
 
In this analysis, we assumed equal bed days for patients in the two treatment arms. 
However, given the poorer efficacy of FLU treatment, admission duration, 
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readmission and complications could be greater, thus increasing the hospital care 
cost of patients receiving FLU monotherapy, and reducing the incremental cost 
between the two treatment options. For example, increasing the number of 
readmission days to 3 with FLU monotherapy versus 2 with the oral combination, 
results in a reduction in ICER from US$65 to US$51 per life year saved. Also, while 
our analysis is based on 10 week outcomes, long term follow-up data shows that the 
survival curve for FLU patients does not plateau after 10 weeks, despite introduction 
of ART. In a prior cohort, patients kept on dying after 10 weeks such that at 1 year, 
survival was less than one quarter [4]. Conversely, long term follow-up data from 
ACTA (Kanyama, Molloy, Harrison, unpublished), confirms our prior experience [17] 
that with appropriate introduction of ART and more fungicidal induction treatment, 
survival curves are almost flat after 10 weeks up to 12 months. 
 
This study provides further strong health economic evidence supporting the urgent 
need to make 5FC widely available to reduce cryptococcal meningitis mortality in 
resource-limited settings, including those currently using FLU monotherapy, and 
where even one week of AmB treatment would be difficult to sustain. 
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Table. Probabilistic cost-effectiveness analyses comparing the trial arms in terms of 
total health care costs cost per patient and death rate per arma 
 
Total costs per patient and death rate 
(%) 
Incremental comparison of 2 weeks of oral 
FLU + 5FC versus oral FLU monotherapy 
  
Treatment 
 
Total costs ($) Deaths (%) Incremental 
costs/patient ($) 
Incremental 
death (%) 
ICER/life 
year saved 
FLU alone 628(557-709) 54(43-64) reference  reference   
FLU + 5FC 847(776-929) 35(29-42) 219(110-329) 19(6-30) 65(28-208) 
aParameters varied in the probabilistic sensitivity analysis are hospital care costs 
(both hospitalisation and re-hospitalisation as these constituted at least 50% of the 
total costs in both arms), and mortality rates in the two arms. To account for 
variations in hospital care costs we used the standard deviation of the number of bed 
days during admission, and for mortality we incorporated the 95% confidence 
intervals. 
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Figure Legend 
Bivariate deterministic sensitivity analysis showing the impact of 5FC price (values 
ranging from US$0 to US$1.60) and FLU death rate (values ranging from 0.45 to 
0.65) on the incremental cost-effectiveness ratio (ICER). All the other parameters 
were held constant at the base case scenario (Supplementary Table S2). 
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